Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical application directed towards hidradenitis suppurativa (HS) – a highly stigmatizing and chronic inflammatory condition characterized by severe pain, malodorous drainage and permanent scarring of the armpits and groin. The company was founded 2019 by former Novozymes A/S scientist and current CEO Jeppe Mouritsen.

Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.

GutCRINE will pursue development of transformative therapies within the spectrum of metabolic and age-related diseases like obesity, type 2 diabetes, osteoporosis and Parkinson’s disease. GutCRINE is founded by professor and endocrinologist Oluf Borbye Pedersen and co-founder, Assistant Professor Yong Fan.

ArgusEye is a spin-off company from Linköping University, Sweden. The company develops novel sensor systems based on nanoplasmonic sensing, which is an optical technique that enables a robust label-free detection of biomolecular interactions in real-time. By combining nanoplasmonic sensing with fiber optics, ArgusEye has developed a miniaturized sensing system with potential applications including monitoring of biopharmaceutical production processes, detection of pathogens and other contaminants in water systems, and miniaturized sensors for in situ and in vivo detection of biomarkers.=

Moleculent, based in Stockholm, is led by a team of industry veterans with extensive experience in developing and globally commercializing life science tools. Their expertise comes from leading companies such as Halo Genomics (acquired by Agilent), Vanadis Diagnostics (acquired by Perkin Elmer), and Spatial Transcriptomics (acquired by 10x Genomics). Moleculent’s innovative approach allows scientists to study cell-cell interactions between various receptors and ligands within tissue contexts. This represents a paradigm shift in understanding biological systems, enabling scientists to gain a more comprehensive view and decode cell-cell communications and disease pathways.

Purpose Pharma is organized in two business areas: Specialty/Proprietary Products and Unlicensed Medicines. In the Specialty/Proprietary Products business area, it is the company’s mission to identify and develop niche products for commercialization, initially focusing on the Nordics and over time expanding into other European markets. The company has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for its first product, diflunisal, for the treatment of transthyretin amyloid polyneuropathy (ATTR-PN), a rare and debilitating disease and for which orphan drug designation has been granted.

Hoba Therapeutics is Danish biotech developing restorative treatments for pain, hearing loss, and sensory neuron disorders. HB-086 is under development for the treatment of pain in multiple chronic neuropathic pain indications. HB-086 is a non-opioid compound with a unique MoA targeting the peripheral nervous system to reverse neuropathic pain and thus targeting the underlying cause of the disease. HB-097 is a restorative treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage.

Scenic Biotech is leveraging its Cell-Seq discovery platform to identify genetic modifiers across multiple therapeutic areas. Its lead programs include an immuno-oncology program targeting QPCTL, and three rare diseases programs based on druggable genetic modifiers. The rare disease programs consist of; Niemann Pick disease, type C (NP-C1), a rare lipid storage disorder that affects lipid metabolism, and cholesterol are transported in human cells, Barth syndrome, an X-linked, lipid metabolism disorder that affects the heart, and a program to treat a severe heritable metabolic syndrome.

Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation.

Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

Cinclus Pharma is a Swedish biopharmaceutical company that is developing novel small molecules for the treatment of gastroesophageal reflux disease (GERD). The lead candidate, linaprazan glurate, belongs to a novel class of drugs, so called Potassium-Competitive Acid Blockers (P-CABs), that result in faster regulation of intragastric pH by a different mechanism of action compared to PPIs. The drug is in Phase 2 development in Europe and the US and has the potential to heal esophageal injuries and alleviate GERD symptoms more effectively than current pharmaceutical therapies including PPIs.

The company is founded by leading clinical researches at Herlev Hospital in Denmark who showed in clinical trials in lung cancer patients that their proprietary checkpoint/cancer vaccines provided more than 3x increased survival. The company’s lead program is in phase II in melanoma, and additional programs targets head and neck cancers, lung cancer as well as other cancer indications.

Attgeno has developed Supernitro, a first in class therapy for the specific delivery of Nitric Oxide (NO) in the lung for prevention and treatment of pulmonary hypertension. By the donation of NO in the lungs, Supernitro replaces the decrease in NO production that is a well-known consequence of different diseases leading to increased risk for pulmonary hypertension, a condition associated with severe morbidity and mortality.

The Company is based on seminal research from Lund University, Sweden, exploring the role of a group of proteins called Galectins. The lead program is in late stage clinical development and addresses a novel therapeutic target for Ideopatic Pulmonary Fibrosis called Galectin-3. Additional programs targets other fibrotic diseases. Galecto listed on NASDAQ (US) in October 2020 and trades under the ticker symbol GLTO.

The company was founded in Sweden based on Professor Ulrica Nilsson’s research. Rapp aims to implement value-based care by focusing on improving quality of care and overall patient satisfaction after “day surgery” (outpatient surgery) through its well-established monitoring system, while in the meantime enabling the healthcare system to improve an efficient workflow and cut healthcare costs accordingly. Considering trends of increasing number of surgical procedures carried out on a same-day basis in recent years, medical value generated with this digital platform will benefit healthcare systems, patients as well as research community to further improve the processes.

Sortina is a spin-out of Gotenborg University. The company develops new first in class therapies inhibiting sortilins, a group of molecules playing a key role in metastasis and growth of aggressive cancers. Sortina is currently in early development, optimizing its small molecule sortilin inhibitors before entering pre-clinical studies.

SACRA Therapeutics represents a strategic collaborative research enterprise between Cristian Bellodi ‘s team at Lund University and Red Glead Discovery, built upon the original findings by the Bellodi group unravelling key roles for RNA modifications and protein biosynthesis in stem and cancer cells. SACRA Therapeutics addresses unmet clinical needs by developing lead compounds to target RNA modifiers in common tumor types characterized by metabolic dysfunction of protein synthesis and dismal prognosis.

Dania Tx was founded in July 2021 with operations in Copenhagen. The company is based on research from renowned professor Kristian Helin and dr. Karl Agger originating from Helin’s former research group at the University of Copenhagen. The ambition is to develop a treatment for acute myeloid leukemia, however the broad-acting potential gives hope for the treatment to be used for more cancer types, for example other types of leukemia and colorectal and pancreatic cancer.